Nicholas James Ashton

Achieving near single-molecule sensitivity in separation-free protein detection using engineered kinetic proofreading

This paper introduces SPEAR, a separation-free protein detection method that achieves sub-100-molecule sensitivity using engineered kinetic proofreading, outperforming existing methods for Alzheimer's and SARS-CoV-2 biomarkers.

Sex differences in astrocytic reactivity and its association with cognitive decline in cognitively unimpaired older adults

This study examines sex differences in plasma GFAP levels and their association with AD biomarkers and cognitive decline in older adults, finding higher GFAP in females but no consistent sex-specific effects on cognitive decline.

Associations between fluid biomarkers and PET imaging (UCB-J) of synaptic pathology in Alzheimer's disease

The paper examines the relationship between SV2A PET imaging and CSF synaptic protein levels in Alzheimer's disease patients and cognitively normal individuals, finding associations between lower synaptic density and specific protein markers.

Multiplex Proteomics of Lewy Body Dementia Reveals Cerebrospinal Fluid Biomarkers of Clinical and Neuropathological Heterogeneity

This study uses multiplex proteomics to identify CSF biomarkers of clinical and neuropathological heterogeneity in Lewy body dementia.

Hippocampal GFAP-positive astrocyte responses to amyloid and tau pathologies

The paper investigates GFAP-positive astrocyte responses to amyloid-beta and tau pathologies in humans and mouse models, finding distinct molecular signatures associated with each pathology.

Revealing the combined roles of Aβ and tau in Alzheimer's disease via a pathophysiological activity decoder

The paper develops a personalized brain activity model integrating functional MRI, Aβ, and tau-PET to reveal synergistic effects of Aβ and tau on cognitive impairment and neuronal excitability in Alzheimer's disease.

APOE ε4 gene dose effect on imaging and blood biomarkers of glial reactivity and β-amyloid pathology

The paper examines the effect of APOE ε4 gene dose on glial reactivity and β-amyloid pathology in cognitively unimpaired individuals using PET, MRI, and plasma biomarkers.